Understanding how SARS-CoV-2 affects people with HIV
Official title: Mechanisms of SARS-CoV-2 pathogenesis during HIV/SIV infection
Funded at University of Washington · NIH-10914834 · Data updated 2026-11-12
This study is looking at how COVID-19 affects people with weakened immune systems from HIV, to understand why they might get sicker and how the virus changes in their bodies, so we can find better ways to help them stay healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 28, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $785,351 |
| NIH project number | 5R01HL165933-02 |
| Project ID | NIH-10914834 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are at risk for severe COVID-19 outcomes.
✕Less likely to help
Patients who are not living with HIV or who do not have compromised immune systems may not benefit from this research.
What this research studies
This research investigates how SARS-CoV-2, the virus that causes COVID-19, behaves in individuals who are immunocompromised due to HIV infection. It focuses on the mechanisms that lead to severe COVID-19 outcomes in these patients, including prolonged viral infection and the potential for more dangerous virus variants to emerge. By examining the immune responses and the role of the microbiome in both lung and gastrointestinal health, the study aims to uncover critical factors that contribute to severe disease in this vulnerable population.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment strategies for COVID-19 in individuals living with HIV.
How similar studies have gone: Other research has shown that understanding viral interactions in immunocompromised patients can lead to significant advancements in treatment, suggesting this approach has potential for success.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: O'connor, Megan a — University of Washington
- Study coordinator: O'connor, Megan a
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.